financetom
Business
financetom
/
Business
/
Lindsay's Fiscal Q2 Earnings Rise, Revenue Falls
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lindsay's Fiscal Q2 Earnings Rise, Revenue Falls
Apr 4, 2024 4:50 AM

07:40 AM EDT, 04/04/2024 (MT Newswires) -- Lindsay (LNN) reported fiscal Q2 earnings Thursday of $1.64 per diluted share, up from $1.63 a year earlier.

Four analysts polled by Capital IQ expected $1.56.

Total revenue for the quarter ended Feb. 29 was $151.5 million, down from $166.2 million a year earlier.

Three analysts surveyed by Capital IQ expected $172.7 million.

Price: 115.58, Change: +0.23, Percent Change: +0.2

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Okta Enters Multiyear Partnership With McLaren Racing Formula 1 Team; Shares Rise
Okta Enters Multiyear Partnership With McLaren Racing Formula 1 Team; Shares Rise
Jan 28, 2025
10:55 AM EST, 01/28/2025 (MT Newswires) -- Okta ( OKTA ) said Tuesday it will work with McLaren Racing to explore new ways to protect and improve how various McLaren Racing stakeholders access their apps and platforms under a multiyear partnership with the McLaren Formula 1 Team. Okta ( OKTA ) will be an official partner of McLaren for the...
Taboola.com, Reach Extend Multi-Year Agreement
Taboola.com, Reach Extend Multi-Year Agreement
Jan 28, 2025
10:59 AM EST, 01/28/2025 (MT Newswires) -- Taboola.com ( TBLA ) said Tuesday it has renewed its partnership with Reach, a commercial news publisher in the UK and Ireland. In the new multi-year deal, Reach will continue to use Taboola's suit of products to grow its audience and drive revenue across its portfolio spanning the UK, Ireland, and the US,...
Allogene Therapeutics Cleared to Start Phase 1 Testing of ALLO-329 Drug Candidate
Allogene Therapeutics Cleared to Start Phase 1 Testing of ALLO-329 Drug Candidate
Jan 28, 2025
10:54 AM EST, 01/28/2025 (MT Newswires) -- Allogene Therapeutics ( ALLO ) has been cleared by US regulators to begin phase 1 testing of its ALLO-329 drug candidate in patients with systemic lupus erythematosus. The upcoming study approved by the US Food and Drug Administration and slated to begin by mid-2025 takes in several types of rheumatological disorders and will...
Fenbo Receives Nasdaq Noncompliance Notice
Fenbo Receives Nasdaq Noncompliance Notice
Jan 28, 2025
10:57 AM EST, 01/28/2025 (MT Newswires) -- Fenbo Holdings ( FEBO ) said Tuesday it received a Nasdaq noncompliance notice on Jan. 16 for failing to hold its annual meeting of stockholders within 12 months for its fiscal year ended on Dec. 31, 2023. The company has 45 calendar days, or until March 3, to submit a plan for regaining...
Copyright 2023-2026 - www.financetom.com All Rights Reserved